Antidiabetic Drug Improves Glycemic Control, Insulin Sensitivity

Susan Farley
Published Online: Friday, October 1, 2004

A long-term study of the oral antidiabetic drug pioglitazone HCl (Actos) revealed that its use either alone or in combination with other oral antidiabetic medications resulted in sustained improvements in glycemic control, insulin sensitivity, and prominent lipid parameters. Conducted over a 2-year period, the study combined pioglitazone HCl with 2 other common antidiabetic medications: gliclazide and metformin. More than 1200 patients were followed over the 2-year period, and 4 different regimens were evaluated.

The results showed that, regardless of whether pioglitazone HCl was combined with metformin or with gliclazide, there was a significant reduction in fasting insulin, and these decreases were sustained over a period of 2 years. Researchers determined that Actos helps the body use its insulin more efficiently, thereby reducing fasting insulin and reducing demand on the pancreatic beta cells.

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues